This site is intended for UK healthcare professionals

 
Sponsorship statement:
Novartis Pharmaceuticals UK Ltd has provided OmniaMed Communications Ltd with an arm’s length sponsorship towards the development of the British Journal of Cardiology Masterclasses in Heart Failure.
novartis-logo-transparent

Masterclass: Heart failure in primary care

4 January 2024
Available for 1 CPD point(s)

Masterclass

Watch Ahmet Fuat and Maggie Simpson discuss the recent guidelines for the diagnosis, classification and management of heart failure, including a discussion on the phenotypic subtypes and applicable updated treatment strategies that can help manage your patients with heart failure.

Speakers

Professor Ahmet Fuat GP with special interest in cardiology, Darlington, and Honorary Professor of Primary Care Cardiology, Durham University
Maggie Simpson Cardiology Advanced Nurse Practitioner — Heart failure,  NHS Greater Glasgow and Clyde

Learning objectives

    • Prevalence and burden of heart failure

    • Definition and diagnostic criteria for different classes of heart failure 

    • Recommendations for primary prevention of heart failure

    • Causes and symptoms of heart failure

    • Classification of heart failure according to symptoms
     
    • Management and treatment strategies for heart failure
     
    • Guidelines and QOF for follow up of treatment

       

    Learning module instructions

    This BJC TV Learning module has a recommended award of 1 CPD credit for completion (1 hour of learning).
    Completion requires a score of at least 80%. If less time is spent learning, then you should claim a reduced credit value.
    After you have successfully completed the test you will be able to download your certificate.

    References

    1. Taylor CJ et al. BMJ 2019;364:I223. https://doi.org/10.1136/bmj.l223

    2. McDonagh TA et al. Eur Heart J 2023;44(37):3627–3639. https://doi.org/10.1093/eurheartj/ehad195

    3. McDonagh TA et al. Eur Heart J 2021;42:3599–3726. https://doi.org/10.1093/eurheartj/ehab368

    4. Yancy CW et al. Circulation 2013;128:e240–e327. https://doi.org/10.1161/CIR.0b013e31829e8776

    5. Vaduganathan M et al. Lancet 2020;396:121–128. https://doi.org/10.1016/S0140-6736(20)30748-0

    AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.

    AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.

     

    Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.